SecBot SecBot

AZN drug pipeline

ASTRAZENECA PLC · 11 rated drugs
$184.45
+0.0% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.5%
1-day, median of 35 events
IV rank
No data
No current options data
Rated drugs
11
4 bullish · 1 bearish · 6 neutral
Phase 3 trials
21
0 with results posted

Upcoming catalysts

13 dated
  1. Dec 7, 2026
    eculizumab
    Phase 3 primary completion
  2. Dec 10, 2026
    Baxdrostat/dapagliflozin
    Phase 2 primary completion
  3. Dec 23, 2026
    Benralizumab
    Phase 3 primary completion
  4. Dec 2026
    Budesonide
    Phase 3 primary completion
  5. Jan 4, 2027
    AZD0780
    Phase 3 primary completion
  6. Jan 6, 2027
    Phase 3 primary completion
  7. Jan 11, 2027
    AZD0780
    Phase 3 primary completion
  8. Jan 11, 2027
    Datroway
    Phase 3 primary completion
  9. Jan 13, 2027
    Phase 3 primary completion
  10. Jan 18, 2027
    Savolitinib
    Phase 2 primary completion
  11. Jan 29, 2027
    AZD9550
    Phase 2 primary completion
  12. Feb 1, 2027
    GC012F Injection
    Phase 2 primary completion
  13. Feb 10, 2027
    trastuzumab deruxtecan
    Phase 2 primary completion

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseApproved (Japan); Filed/PDUFA (US); CHMP positive opinion (EU)
Time to marketAlready approved in Japan (September 2026). EU approval expected within weeks following the September 17, 2026 CHMP positive opinion. US FDA decision estimated Q4 2026 (December 31, 2026 per some trackers, though the company has not confirmed an exact PDUFA date).

Klygefa gefurulimab Updated Oct 30

What to watch

The next binary catalyst is the US FDA PDUFA decision, estimated for Q4 2026 (potentially December 31, 2026). An approval would open the world's largest drug market and validate the subcutaneous self-administration advantage. The EU Commission decision, expected within weeks, is a lower-impact event given the CHMP positive opinion already in hand. For a diversified giant like AstraZeneca, neither event alone will dramatically move the stock, but a US approval would solidify the gMG franchise alongside Soliris and Ultomiris.

Bull case
  • First and only dual-binding nanobody C5 inhibitor for gMG, offering once-weekly subcutaneous self-administration that is more convenient than IV alternatives like Soliris and Ultomiris (also AZN/Alexion products).
  • Phase 3 PREVAIL trial met primary and all secondary endpoints with statistical significance, showing reduced hospitalizations and durable symptom improvement.
  • Already approved in Japan (September 2026) and CHMP recommended EU approval (September 17, 2026), de-risking the regulatory pathway.
Bear case
  • The gMG C5 inhibitor space is already crowded with AZN's own Soliris (eculizumab) and Ultomiris (ravulizumab), plus UCB's Zilbrysq (zilucoplan), creating potential for internal and external cannibalization.
  • FcRn blockers (Vyvgart, Rystiggo, Imaavy) offer alternative mechanisms and growing competition in the gMG market.
  • As a large, diversified pharma (market cap ~$180B+), Klygefa's $1-3B peak sales represent a small fraction of AZN's overall revenue, limiting stock-moving potential.
● neutral
Impact
PhaseApproved
Time to marketApproved and marketed since 2015 (first FDA approval Nov 2015)

Tagrisso osimertinib Updated Jul 10

What to watch

Tagrisso is AZN's largest drug at $7.3B in 2025 revenue, but it is already fully de-risked and commercialized. The near-term investor debate centers on how quickly J&J's Rybrevant/lazertinib combo erodes first-line share and how far label expansion (LAURA Stage III) boosts volume, gradual commercial trends, not binary events. Watch quarterly sales growth rates and the LAURA OS readout for the next meaningful update.

Bull case
  • Tagrisso is AZN's #1 drug at $7.3B in FY2025 revenue (+10% CER growth), with strong demand across all approved indications (source: AstraZeneca FY2025 results)
  • Label expanded significantly in 2024 (FLAURA2 + chemo in Feb, LAURA Stage III unresectable in Sept), opening new patient populations and extending the growth runway
  • Patent portfolio protects to ~2032-2038; a US appeals court (July 2026) upheld AZN's win against Pfizer's patent challenge, removing a key overhang (source: Reuters, July 9, 2026)
Bear case
  • J&J's Rybrevant (amivantamab)/Lazcluze (lazertinib) combo beat Tagrisso on overall survival in first-line EGFR-mutated NSCLC (MARIPOSA trial), posing the most credible threat to Tagrisso's first-line standard-of-care position (source: pharmaphorum, appliedclinicaltrialsonline)
  • Several institutional funds exited AZN positions in Q1 2026, including Wells Fargo (-100%, 3.1M shares) and Scotia Capital (-100%, 461K shares), per latest 13F filings
  • Quant signals show a low composite score (-40) and factor alignment of just 1, indicating weak momentum/valuation signals relative to peers
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercialized (since 2019 for initial indication)

trastuzumab deruxtecan Updated Oct 24

What to watch

For investors in AZN, Enhertu is a mature commercial asset driving growth, not a binary catalyst. The next watchpoint is the readout of DESTINY-Gastric04 (Phase 3 in HER2+ gastric cancer, estimated primary completion Aug 2026). For VIVS/VivoSim Labs, the drug is not theirs, they merely tested it on a safety platform, so any trading thesis tied to trastuzumab deruxtecan should not involve VIVS stock.

Bull case
  • Enhertu is a best-in-class HER2-directed ADC with a differentiated payload (topoisomerase I inhibitor) vs T-DM1, enabling activity in HER2-low tumors where T-DM1 is inactive.
  • Multiple label expansions into early-stage/curative-intent breast cancer (FDA & EU approvals in 2026) significantly expand the addressable patient population and duration of therapy.
  • Tumor-agnostic approval (EU CHMP positive opinion May 2026, already approved in the US) opens up a broad new patient pool across many HER2-positive solid tumor types regardless of origin.
Bear case
  • Interstitial lung disease (ILD) is a known serious safety risk associated with Enhertu, which could lead to label restrictions or market withdrawal if incidence rises.
  • Enhertu faces growing competition from other HER2-directed ADCs (e.g., trastuzumab emtansine/T-DM1, ARX788, and bispecifics), potentially eroding market share in the long run.
  • Pricing and reimbursement pressure in ex-US markets (especially EU and China) could cap peak sales below current expectations.
▼ bearish
Impact
PhaseApproved
Time to marketAlready approved (Dec 2023 in US; March 2025 in EU). ATTR-CM indication now likely delayed 3-5+ years if pursued at all.

Wainua eplontersen Updated Jul 9

What to watch

Wainua's CARDIO-TTRansform Phase 3 failure in ATTR-CM (July 9, 2026) effectively closes off the much larger cardiomyopathy opportunity. Focus on the August 2026 ESC presentation for whether the monotherapy subgroup signal is strong enough to justify a second trial. For AZN, this is a manageable pipeline setback; IONS shareholders face a more meaningful valuation reset since ATTR-CM was a key growth driver for that stock.

Bull case
  • Wainua is already approved and generating growing commercial revenue, $212M global sales in 2025, with royalty revenue of $49M to Ionis.
  • A prespecified monotherapy subgroup in CARDIO-TTRansform showed a nominally significant reduction in events, suggesting the drug may still work in patients not on a TTR stabilizer, potentially supporting a narrower ATTR-CM path forward.
  • The autoinjector formulation (supplemental FDA approval Dec 2025) and self-administration are competitive advantages vs. infused competitors in hATTR-PN.
Bear case
  • The CARDIO-TTRansform Phase 3 trial failed its primary endpoint, meaning Wainua added to standard of care showed no statistical benefit on CV mortality or recurrent CV events in ATTR-CM, effectively closing off the largest addressable market.
  • ATTR-CM is a $4B+ market where Pfizer's tafamidis is entrenched and BridgeBio's acoramidis and Alnylam's vutrisiran are already approved, Wainua is now at a competitive disadvantage.
  • The failed trial enrolled 1,432 patients across 20 countries, one of the largest ATTR-CM trials ever, making the negative result statistically robust, not a fluke.
● neutral
Impact
PhaseApproved (Japan); Phase 3 completed globally
Time to marketAlready approved and launched in Japan (September 2026) for kappa-type dominant AL amyloidosis. An EU marketing authorization application is under review by the EMA, but no specific decision date is specified. No US BLA filing has been filed in the US as of October 2026.

Amlypave anselamimab Updated Oct 30

What to watch

Watch for the EU CHMP opinion and European Commission decision on the anselamimab marketing authorization application, which would open the European market. Watch for any US BLA filing announcement, which would create a new PDUFA catalyst. For now, the drug is already approved in Japan and the key binary readout (Phase 3) is past, so the stock-moving binary events are behind it for the near term.

Bull case
  • First-in-class anti-fibril mechanism that directly removes amyloid deposits, addressing a clear unmet need in AL amyloidosis where no approved therapy targets the fibrils themselves.
  • Japan approval in September 2026 provides a commercial foothold and regulatory validation for the kappa-subgroup strategy.
  • The kappa-subgroup data (62% survival improvement, 71% reduction in cardiovascular hospitalizations) is clinically meaningful and biologically plausible, and the drug was well-tolerated with a manageable safety profile.
Bear case
  • The Phase 3 CARES program failed its primary endpoint in the overall AL amyloidosis population, a significant setback that limits the drug's addressable market to only kappa-type patients (~18% of patients).
  • The kappa subgroup benefit is based on only ~72 patients, a small sample that raises questions about robustness for broader regulatory approvals.
  • AstraZeneca is a mega-cap pharma giant (~$186/share, analyst consensus Buy with mean target of ~$206.66); this single drug is a minor pipeline asset in a company with dozens of approved drugs and hundreds of pipeline programs.
▲ bullish
Impact
PhaseApproved
Time to marketAlready approved and marketed (first US approval Jan 2025, three indications now approved)

Datroway datopotamab deruxtecan Updated Jul 3

What to watch

Watch AstraZeneca's quarterly earnings for Datroway sales growth as a commercial read-through. The ongoing TROPION-Lung trials (first-line NSCLC) could expand the addressable market materially if positive, but those readouts have no firm dates yet. The main competitive risk is Gilead's Trodelvy, but Datroway appears to have an efficacy and dosing edge.

Bull case
  • Peak sales guided above $5B by AstraZeneca, with rapid uptake, JPY 47.6B (~$315M) in Daiichi Sankyo FY2025 alone, treating 4,900+ patients since launch.
  • Demonstrated statistically significant overall survival and progression-free survival benefit in Phase 3 TROPION-Breast02 trial, with ~2-year median OS in 1L TNBC, the only TROP2 ADC to show OS benefit in that setting.
  • At ESMO 2025, Datroway showed a slight efficacy edge (43% vs 38% reduction in progression risk) and better dosing convenience (once vs twice per cycle, shorter infusion) over Gilead's Trodelvy, the main competitor.
Bear case
  • Datroway is one drug in a massive pipeline, AstraZeneca targets $80B in annual revenue. Even a blockbuster $5B peak is ~6% of that goal. Positive catalysts move the stock incrementally, not dramatically.
  • Trodelvy (Gilead) remains a formidable competitor with established market presence, and Merck has a TROP2 ADC (sacituzumab tirumotecan) in late-stage development, threatening to fragment the category.
  • The EGFR-mutated NSCLC approval is accelerated and may require confirmatory trials for full approval, a failure could cause label restrictions.
● neutral
Impact
PhaseApproved
Time to marketAlready on the market since 2003; the 2026-2027 seasonal formulation is currently available.

FluMist influenza vaccine live intranasal Updated Oct 30

What to watch

FluMist is an already-approved, seasonal product with no binary regulatory catalysts on the horizon. The key commercial metric to watch is whether FluMist Home (at-home delivery) drives meaningful market share gains in the 2026-2027 flu season, but given FluMist's small contribution to AstraZeneca's ~$62B revenue base, even a strong season would barely move the stock. The next meaningful event would be the 2027-2028 strain composition update, which is routine and non-binary.

Bull case
  • FluMist is the only FDA-approved nasal spray flu vaccine in the US, giving it a unique product differentiation versus all injectable competitors.
  • The 2024 FDA approval for self- or caregiver-administration and the 2025 launch of FluMist Home (at-home mail delivery) opened a new convenience channel that could expand the flu vaccine market and grow FluMist's share.
  • FluMist has been on the market since 2003 with a well-established safety and efficacy profile, and it is reformulated annually to match circulating strains per WHO/CDC recommendations.
Bear case
  • FluMist is a tiny revenue contributor within AstraZeneca's massive ~$62B portfolio; vaccines and immune therapies combined were only ~$846M in 2025, so even strong FluMist sales barely move the needle for AZN stock.
  • Competition in the flu vaccine market is intense and growing: Sanofi (Fluzone, Fluad), CSL Seqirus (Flucelvax, Afluria), and emerging mRNA flu vaccines from Moderna and Pfizer all compete for market share.
  • FluMist has a restricted age indication (2-49 years) and is not recommended for certain populations (pregnant women, immunocompromised), limiting its addressable market versus injectable flu vaccines that cover all ages 6 months+.
● neutral
Impact
PhaseApproved (China); Phase 3 first-line data filed for approval
Time to marketAlready approved in China (the 6-K calls it an "approved asset"); US/EU timeline not yet announced by AstraZeneca

sunvozertinib Updated Aug 17

What to watch

Watch for (1) the China first-line indication decision and (2) any AstraZeneca regulatory submissions for Zegfrovy in the US/EU, plus whether AZN pays out the up-to-$900M milestones to Dizal, milestone payouts signal successful global filings. Treat this as franchise-building context for AZN's lung-cancer portfolio (Tagrisso et al.), not a standalone share-price event: the $600M upfront is tiny relative to AZN's market cap.

Bull case
  • AstraZeneca got exclusive GLOBAL rights to an already-APPROVED oral EGFR exon-20-insertion lung-cancer drug, a rare de-risked, commercial-stage bolt-on, for $600M upfront plus up to $900M milestones and tiered royalties.
  • Positive Phase III data have already been filed for the first-line indication, so a label expansion into earlier-line treatment is in motion (AZN 6-K report, 2026-07-14).
  • It slots into AZN's dominant lung-cancer franchise: the same week's data flow (SAFFRON Phase III) underscores Tagrisso's strength in EGFR-mutant NSCLC, and sunvozertinib adds a complementary mechanism for the exon-20 subset (AZN 6-K, 2026-08-17).
Bear case
  • Not approved in the US or EU: SecBot FDA data shows no sunvozertinib action or catalyst on file, so the global story still depends on future filings and decisions with no publicly dated binary in the next 12 months.
  • Competition: AZN's own 6-K risk commentary flags competing therapies such as amivantamab combinations already limiting market share in the EGFR-mutant NSCLC space (SAFFRON 6-K report, 2026-08-17).
  • Immaterial size for AZN: a $600M upfront (plus contingent milestones) against a ~$240-260B market cap means the deal alone cannot meaningfully move the stock, the defining binary for AZN shareholders is elsewhere.

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, bull and bear case and thesis.

Subscribe for Full Access

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, bull and bear case and thesis.

Subscribe for Full Access

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, bull and bear case and thesis.

Subscribe for Full Access

Other drugs in filings and trials

no drug report yet
  • KOSELUGO Last: Approval · Sep 10, 2025
  • VOYDEYA Last: Approval · Mar 29, 2024
  • TRUQAP Last: Approval · Nov 16, 2023
  • BEYFORTUS Last: Approval · Jul 17, 2023
  • SYMBICORT AEROSPHERE Last: Approval · Apr 28, 2023
  • AIRSUPRA Last: Approval · Jan 10, 2023
  • IMJUDO Last: Approval · Nov 10, 2022
  • CALQUENCE Last: Approval · Aug 3, 2022
  • TEZSPIRE Last: Approval · Dec 17, 2021
  • SAPHNELO Last: Approval · Jul 30, 2021
  • BREZTRI AEROSPHERE Last: Approval · Jul 23, 2020
  • QTERNMET XR Last: Approval · May 2, 2019
  • ULTOMIRIS Last: Approval · Dec 21, 2018
  • LOKELMA Last: Approval · May 18, 2018
  • FASENRA Last: Approval · Nov 14, 2017
  • BYDUREON BCISE Last: Approval · Oct 20, 2017
  • QTERN Last: Approval · Feb 27, 2017
  • BEVESPI AEROSPHERE Last: Approval · Apr 25, 2016
  • KANUMA Last: Approval · Dec 8, 2015
  • NEXIUM 24HR Last: Approval · Nov 23, 2015
  • STRENSIQ Last: Approval · Oct 23, 2015
  • IRESSA Last: Approval · Jul 13, 2015
  • XIGDUO XR Last: Approval · Oct 29, 2014
  • EPANOVA Last: Approval · May 5, 2014
  • FARXIGA Last: Approval · Jan 8, 2014
  • BYDUREON PEN Last: Approval · Jan 27, 2012
  • ALXN2420 1 trial
  • AZD0780 2 trials
  • AZD2936 1 trial
  • AZD7798 1 trial
  • Baxdrostat/dapagliflozin 1 trial
  • Benralizumab 1 trial
  • Budesonide 1 trial
  • Danicopan 1 trial
  • DexamethasoneGroup III (n=25) (Dexamethasone group) 1 trial
  • Durvalumab 1 trial
  • eculizumab 1 trial
  • Furosemide 40 mg 1 trial
  • GC012F Injection 1 trial
  • Magnesium 1 trial
  • Olaparib 1 trial
  • Ravulizumab 1 trial

Past FDA events & how the stock moved

35 events
DateDrugEvent1 day5 days
Sep 10, 2025KOSELUGOApproval−0.1%−4.3%
Mar 29, 2024VOYDEYAApproval−0.7%−0.4%
Dec 21, 2023WainuaApproval+0.8%+2.4%
Nov 16, 2023TRUQAPApproval+1.6%+2.2%
Jul 17, 2023BEYFORTUSApproval−0.9%+2.3%
Apr 28, 2023SYMBICORT AEROSPHEREApproval−0.4%+2.0%
Jan 10, 2023AIRSUPRAApproval−0.6%−0.0%
Nov 10, 2022IMJUDOApproval+2.8%+4.9%
Oct 21, 2022IMJUDOApproval+1.5%+8.0%
Aug 3, 2022CALQUENCEApproval+1.6%+1.6%
Dec 17, 2021TEZSPIREApproval−0.9%+1.7%
Jul 30, 2021SAPHNELOApproval−0.5%−2.1%
Jul 23, 2020BREZTRI AEROSPHEREApproval−2.1%+1.6%
Apr 10, 2020KOSELUGOApproval+6.0%+12.0%
May 2, 2019QTERNMET XRApproval+2.8%+3.0%
Dec 21, 2018ULTOMIRISApproval−3.1%−0.2%
May 18, 2018LOKELMAApproval+1.0%+1.6%
Nov 14, 2017FASENRAApproval+1.5%+2.5%
Oct 31, 2017CALQUENCEApproval+2.3%−0.5%
Oct 20, 2017BYDUREON BCISEApproval−0.9%−3.5%
Aug 17, 2017LynparzaApproval−0.2%+1.0%
May 1, 2017ImfinziApproval+1.5%−0.1%
Feb 27, 2017QTERNApproval−0.3%+0.9%
Apr 25, 2016BEVESPI AEROSPHEREApproval−1.7%−2.7%
Dec 8, 2015KANUMAApproval−1.6%−2.1%
Nov 23, 2015NEXIUM 24HRApproval−0.4%+2.0%
Nov 13, 2015TagrissoApproval+6.3%+10.5%
Oct 23, 2015STRENSIQApproval+1.3%+2.6%
Jul 13, 2015IRESSAApproval+2.1%+2.1%
Dec 19, 2014LynparzaApproval−0.0%−1.9%
Oct 29, 2014XIGDUO XRApproval+1.6%+2.9%
May 5, 2014EPANOVAApproval−2.4%−3.9%
Mar 28, 2014NEXIUM 24HRApproval−0.1%−0.8%
Jan 8, 2014FARXIGAApproval+1.5%+7.6%
Jan 27, 2012BYDUREON PENApproval−0.1%−0.8%

Clinical trials

39 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
trastuzumab deruxtecanA Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing TumorsPhase 2Active not recruiting127Feb 10, 2027
GC012F InjectionA Study of GC012F Injection in Subjects With Refractory Systemic Lupus ErythematosusPhase 2Active not recruiting20Feb 1, 2027
AZD9550A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and OverweightPhase 2Active not recruiting166Jan 29, 2027
SavolitinibSavolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLCPhase 2Active not recruiting47Jan 18, 2027
—A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With TezepelumabPhase 3Active not recruiting181Jan 13, 2027
AZD0780A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD EventPhase 3Active not recruiting3,103Jan 11, 2027
DatrowayA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerPhase 3Active not recruiting768Jan 11, 2027
—Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)Phase 3Active not recruiting314Jan 6, 2027
AZD0780A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFHPhase 3Active not recruiting473Jan 4, 2027
BenralizumabA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic AsthmaPhase 3Active not recruiting94Dec 23, 2026
Baxdrostat/dapagliflozinA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.Phase 2Active not recruiting222Dec 10, 2026
eculizumabEfficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSDPhase 3Active not recruiting21Dec 7, 2026
BudesonideOnce Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoEPhase 3Active not recruiting308Dec 2026
—A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus ErythematosusPhase 3Active not recruiting339Nov 2, 2026
Dapagliflozin 10 MG Oral TabletEffect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)Phase 3Completed44Oct 30, 2026
DurvalumabDetermining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung CancerPhase 2Completed61Oct 20, 2026
—Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA TreatmentPhase 3Completed130Sep 21, 2026
DexamethasoneGroup III (n=25) (Dexamethasone group)Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor PatientsPhase 3Completed75Sep 20, 2026
AZD0780A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With DyslipidaemiaPhase 2Completed76Sep 3, 2026
Furosemide 40 mgSalt-Sensitivity and Immunity Cell ActivationPhase 2Completed36Sep 1, 2026
trastuzumab deruxtecanTrastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)Phase 3Active not recruiting490Aug 31, 2026
AZD2936A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCPhase 2Active not recruiting212Aug 28, 2026
AZD9833A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseasePhase 3Active not recruiting1,370Aug 24, 2026
AZD7798Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an IleostomyPhase 2Active not recruiting24Aug 20, 2026
Nexium 20mgEndoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.Phase 3Completed53Aug 10, 2026
DanicopanA Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNHPhase 3Active not recruiting80Jul 31, 2026
BevespiInhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPDPhase 2Completed25Jul 31, 2026
OlaparibD9319C00001- 1L OC Mono Global RCTPhase 3Active not recruiting366Jul 27, 2026
RavulizumabEvaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia GravisPhase 3Active not recruiting12Jul 15, 2026
TezepelumabEfficacy and Safety of Tezepelumab in Patients With Eosinophilic EsophagitisPhase 3Active not recruiting368Jul 14, 2026
DapagliflozinRandomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular EdemaPhase 2Completed56Jul 14, 2026
TagrissoTo Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR MutationsPhase 2Active not recruiting76Jul 7, 2026
trastuzumab deruxtecanTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)Phase 3Active not recruiting1,157Jul 6, 2026
DurvalumabA US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TAREPhase 2Active not recruiting58Jul 1, 2026
OleclumabA Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)Phase 2Active not recruiting30Jun 30, 2026
MagnesiumA Study of Magnesium and Bladder Spasms Following Ambulatory Urologic ProceduresPhase 2Completed120Jun 30, 2026
DurvalumabA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerPhase 3Active not recruiting1,051Jun 30, 2026
ALXN2420ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With AcromegalyPhase 2Terminated8Jun 24, 2026
CabazitaxelStudy of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPCPhase 2Completed96Jun 10, 2026

1 newer trial for subscribers. See plans